print_label | resize_label

Welcome to the
Zoladex prostate cancer information centre

In the UK, prostate cancer is the most common type of cancer in men, with around 46,690 new cases diagnosed each year. 1

This website gives you all the information you need about the prostate cancer treatment Zoladex (goserelin), a type of treatment known as luteinising hormone-releasing hormone analogues (LHRHa’s).

Whether you’re new to Zoladex, or your doctor has given it to you before, you can create your own personal information pack using our

Interactive Bookbuilder application

Zoladex branding image

The Zoladex patient information leaflet (PIL) is available to download here:

Reporting of side effects

Like all medicines, Zoladex can cause side effects, although not everybody gets them.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: By reporting side effects you can help provide more information on the safety of this medicine.

AstraZeneca does not control the content of any external websites 

  1. Cancer Research UK: Prostate cancer incidence statistics:
    (Last accessed July 2017).

GB-6242. Date of Preparation: Sept 2017